Daily Maverick

DM is much better if you are signed in...

Enter your email below and we will send you a mail with a link or one-time pin to login

Sign in with OAuth

Get Support DM Shop Support DM

Novo Nordisk

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

World

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

By Reuters

A dose of their own medicine — should SA force big drugmakers to let others make insulin pens too?

Maverick Citizen

A dose of their own medicine — should SA force big drugmakers to let others make insulin pens too?

By Christina Pitt

Doctors Without Borders calls on big pharma to continue supply of insulin pens as contract ends

South Africa

Doctors Without Borders calls on big pharma to continue supply of insulin pens as contract ends

By Estelle Ellis

The rise of Ozempic: how surprise discoveries and lizard venom led to a new class of weight-loss drugs

Maverick Life

The rise of Ozempic: how surprise discoveries and lizard venom led to a new class of weight-loss drugs

By Sebastian Furness

Aspen’s Novo Nordisk deal a ‘feather in our cap’ and an NCD battle boost - top executive

Business Maverick

Aspen’s Novo Nordisk deal a ‘feather in our cap’ and an NCD battle boost - top executive

By Georgina Crouth

Aspen’s Covid vaccine facility in Gqeberha switches to making insulin for Africa

South Africa

Aspen’s Covid vaccine facility in Gqeberha switches to making insulin for Africa

By Estelle Ellis

Global stocks of diabetes drug Ozempic drained by doctors prescribing it for weight loss

South Africa

Global stocks of diabetes drug Ozempic drained by doctors prescribing it for weight loss

By Zano Kunene